GEMALTO
6.3.2019 07:02:16 CET | Business Wire | Press release
Gemalto, the world leader in digital security, today announced the availability of three new cloud-based Hardware Security Module (HSM) services, HSM On Demand for CyberArk , HSM On Demand for Hyperledger and HSM On Demand for Oracle TDE . Each service is available through the SafeNet Data Protection on Demand platform, a marketplace of cloud-based HSM, encryption and key management services that easily integrates with most widely used cloud services and IT products to protect data wherever it is created, accessed or stored.
The rapid adoption of cloud and digital services has made it difficult for organizations to secure data and identities that are created, stored and managed outside the perimeter. While organizations recognize that data encryption is the optimal solution to secure sensitive information, they can be challenged by the cost and complexity of deploying encryption, including Hardware Security Modules to secure their cryptographic operations. Gemalto’s SafeNet Data Protection On Demand solves these challenges by providing cloud-based HSM services that and can be deployed in minutes without the need for highly skilled staff. Gemalto, a leader in the HSM market, is proven to help customers secure their encryption keys and data across cloud, hybrid, and on-premises environments.
“A worsening threat landscape, combined with aggressive cloud adoption and evolving privacy regulations, have presented complex new challenges related to encryption, privileged access and financial transactions,” said Todd Moore, Senior Vice President of Encryption Products at Gemalto. “Our newest Cloud HSM On Demand services help organizations stay in front of new threats and regulations, by easily deploying an HSM solution for the strongest possible key management and security practices, all while providing fast, easy set-up, with remarkable savings over traditional approaches involving specialized hardware and skills.”
“Many organizations would like to deploy data security more broadly, but are often wary due to concerns about complexity, cost and staffing requirements, particularly with respect to encryption and key management,” said Garrett Bekker, Principal Analyst at 451 Research. “The release of SafeNet Data Protection On Demand was a positive step towards addressing those concerns, and extending its cloud HSM capability to newer use cases like blockchain, database security and privileged credentials is a logical and timely move.”
HSM On Demand for CyberArk
HSM
On Demand for CyberArk
works seamlessly with CyberArk’s Privileged
Access Security Solution, providing private key protection and strong
entropy for key generation for system keys.. By securing the master key
and ensuring that it is hosted in a secure vault, HSM On Demand for
CyberArk mitigates the risk of the master key being exposed or
compromised.
HSM On Demand for Hyperledger
HSM
On Demand for Hyperledger
provides trust for blockchain transactions
by securing the cryptographic keys that sign them. It protects digital
wallets, while ensuring keys are readily available in the cloud once
access is granted. The service provides high assurance security in data
centers and the cloud, enabling multi-tenancy of blockchain identities
per partition as proof of transaction and for auditing requirements. It
also delivers performance improvements resulting from off-loading
cryptographic operations from application servers to the HSM on Demand
service.
HSM On Demand for Oracle TDE
HSM
for Oracle TDE
(Transparent Data Encryption) solves the challenge
presented by locally stored encryption keys by protecting them with a
master key, stored in a separate service key vault. This ensures that
only authorized services are allowed to request the local key to be
decrypted. If an attacker steals the database, it is encrypted and
inaccessible, since the attacker does not have access to the keys that
are securely stored on the HSM.
Additional Resources
- HSM On Demand for CyberArk Overview
- HSM on Demand for CyberArk Integration Guide
- HSM On Demand for Hyperledger Integration Guide
- HSM On Demand for Oracle TDE Integration Guide
- Blog: Choosing the Right Cloud HSM
About Gemalto
Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security , with 2018 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.
From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.
Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.
Our 15,000 employees operate out of 110 offices, 47 personalization and data centers, and 35 research and software development centers located in 47 countries.
For more information visit www.gemalto.com , or follow @gemalto on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190305005648/en/
Contact:
Gemalto media contacts: Tauri Cox North America +1 512 257 3916 tauri.cox@gemalto.com
Sophie Dombres Europe Middle East & Africa +33 4 42 36 57 38 sophie.dombres@gemalto.com
Jaslin Huang Asia Pacific +65 6317 3005 jaslin.huang@gemalto.com
Alexis Camarillo Latin America +52 5521223627 alexis.camarillo@gemalto.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
